McKesson Buys Precision Medicine for $2.25B

McKesson Corporation has entered into an agreement to acquire Precision Medicine Group for an estimated $2.25 billion. This strategic acquisition is designed to expand McKesson's existing clinical research and commercialization services.

Precision Medicine Group offers integrated services and technology-enabled products that support advanced drug development. Biotechnology and pharmaceutical firms utilize its offerings, which include biomarker intelligence and global clinical research organization capabilities.

Upon finalizing the deal, Precision Medicine Group will be incorporated into McKesson's Oncology & Multispecialty segment. This segment represented $14.2 billion in sales during the first quarter, making it McKesson's second-largest.

McKesson concluded the first quarter with cash and equivalents totaling $5.20 billion. The company's stock has shown a positive long-term trend, increasing by 28.70% over the past 12 months and trading above key moving averages.

However, technical indicators suggest a mixed short-term outlook. While the stock is trading above its 20-day and 50-day simple moving averages, a death cross occurred in June, with the 50-day SMA still below the 200-day SMA. Momentum, as indicated by MACD, is currently showing pressure cooling, suggesting potential consolidation before further advances.

Key resistance is noted at $907.00, with support identified at $744.50. Analysts maintain a positive consensus, holding a Buy rating with an average price target of $986.56.